TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
Background: Due to high invasiveness and heterogeneity, the morbidity and mortality of intrahepatic cholangiocarcinoma (ICC) remain unsatisfied. Recently, the exploration of genomic variants has decoded the underlying mechanisms of initiation and progression for multiple tumors, while has not been f...
Main Authors: | Chunguang Guo, Zaoqu Liu, Yin Yu, Yunfang Chen, Hui Liu, Yaming Guo, Zhenyu Peng, Gaopo Cai, Zhaohui Hua, Xinwei Han, Zhen Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.844800/full |
Similar Items
-
Frequency and effects of mutations in the KRAS gene on the survival of patients after surgical treatment of intrahepatic cholangiocarcinoma
by: B. N. Gurmikov, et al.
Published: (2020-04-01) -
KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
by: Zheng Gao, et al.
Published: (2022-03-01) -
Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
by: Peng Jianbo, et al.
Published: (2023-07-01) -
Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
by: Rebecca Marcus, et al.
Published: (2021-11-01) -
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
by: Ze Zhang, et al.
Published: (2021-09-01)